Biogen

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,500

Employees7,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,500

Employees7,500

BIIB Key Statistics

Market cap

28.62B

Market cap28.62B

Price-Earnings ratio

20.79

Price-Earnings ratio20.79

Dividend yield

—

Dividend yield—

Average volume

1.36M

Average volume1.36M

High today

$194.41

High today$194.41

Low today

$190.00

Low today$190.00

Open price

$190.52

Open price$190.52

Volume

799.97K

Volume799.97K

52 Week high

$205.97

52 Week high$205.97

52 Week low

$121.05

52 Week low$121.05

Stock Snapshot

The current Biogen(BIIB) stock price is $193.76, with a market capitalization of 28.62B. The stock trades at a price-to-earnings (P/E) ratio of 20.79.

During the trading session on 2026-05-23, Biogen(BIIB) shares reached a daily high of $194.41 and a low of $190.00. At a current price of $193.76, the stock is +2.0% higher than the low and still -0.3% under the high.

Trading volume for Biogen(BIIB) stock has reached 799.97K, versus its average volume of 1.36M.

The stock's 52-week range extends from a low of $121.05 to a high of $205.97.

BIIB News

TipRanks 1d

Denali, Biogen Halt Parkinson’s Trial After Efficacy Failure

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 2d

Biogen and Denali’s Parkinson’s candidate did not meet Phase 2b endpoints

Biogen (BIIB) and Denali Therapeutics (DNLI) announced topline results from the Phase 2b LUMA study evaluating BIIB122, an investigational small molecule inhibi...

Simply Wall St 3d

How Biogen’s Diranersen Alzheimer’s Bet Will Impact Biogen Investors

Earlier in May 2026, Biogen reported topline Phase 2 CELIA data for diranersen in early Alzheimer’s disease, showing robust tau reductions and signals of slowed...

Analyst ratings

55%

of 38 ratings

Buy

55.3%

Hold

39.5%

Sell

5.3%

More BIIB News

Simply Wall St 3d

Ionis Rises As Diranersen Phase 2 Spurs Biogen Registrational Plans

Biogen and Ionis reported topline Phase 2 CELIA data for diranersen in early Alzheimer's disease, showing robust biomarker and cognitive effects. The antisense...

TipRanks 4d

Biogen Earnings Call Signals Confident, Investment-Heavy Transition

Biogen Inc. ((BIIB)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level data and powerfu...

Simply Wall St 5d

Assessing Biogen Valuation After Recent Share Price Momentum And Earnings Expectations

Advertisement Biogen stock reaction and recent performance snapshot Biogen (BIIB) has been in focus for investors after recent trading left the stock at a las...

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.